Vapiprost hydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341399

CAS#: 87248-13-3

Description: Vapiprost hydrochloride is a biochemicla.


Price and Availability

Size
Price

1mg
USD 305
Size
Price

5mg
USD 775
Size
Price

Vapiprost hydrochloride purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 341399
Name: Vapiprost hydrochloride
CAS#: 87248-13-3
Chemical Formula: C30H40ClNO4
Exact Mass: 513.2646
Molecular Weight: 514.103
Elemental Analysis: C, 70.09; H, 7.84; Cl, 6.90; N, 2.72; O, 12.45


Synonym: Vapiprost hydrochloride; GR 32191B; GR-32191B; GR32191B.

IUPAC/Chemical Name: 4-Heptenoic acid, 7-(5-((1,1'-biphenyl)-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl)-, hydrochloride, (1R-(1alpha(Z),2beta,3beta,5alpha))-

InChi Key: ZYOBZRTZRQKKNC-UGNABIHOSA-N

InChi Code: InChI=1S/C30H39NO4.ClH/c32-27-21-28(35-22-23-15-17-25(18-16-23)24-11-5-3-6-12-24)26(13-7-1-2-8-14-29(33)34)30(27)31-19-9-4-10-20-31;/h1-3,5-6,11-12,15-18,26-28,30,32H,4,7-10,13-14,19-22H2,(H,33,34);1H/b2-1-;/t26-,27-,28-,30+;/m0./s1

SMILES Code: O=C(O)CC/C=C\CC[C@@H]1[C@@H](N2CCCCC2)[C@@H](O)C[C@@H]1OCC3=CC=C(C4=CC=CC=C4)C=C3.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Cracowski JL, Stanke-Labesque F, Devillier P, Chavanon O, Hunt M, Souvignet C, Bessard G. Human internal mammary artery contraction by isoprostaglandin f(2alpha) type-III [8-iso-prostaglandin F(2alpha)]. Eur J Pharmacol. 2000 May 26;397(1):161-8. PubMed PMID: 10844110.

2: Barchasz E, Naline E, Molimard M, Moreau J, Georges O, Emonds-Alt X, Advenier C. Interleukin-1beta-induced hyperresponsiveness to [Sar9,Met(O2)11]substance P in isolated human bronchi. Eur J Pharmacol. 1999 Aug 20;379(1):87-95. PubMed PMID: 10499376.

3: Horie S, Yamada M, Satoh M, Noritake S, Hiraishi S, Kizaki K, Kurusu O, Nakahara T, Ishii H, Kazama M. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. Biol Pharm Bull. 1997 Jun;20(6):625-31. PubMed PMID: 9212979.

4: Molimard M, Martin CA, Naline E, Hirsch A, Advenier C. Role of thromboxane A2 in bradykinin-induced human isolated small bronchi contraction. Eur J Pharmacol. 1995 May 4;278(1):49-54. PubMed PMID: 7545124.

5: Ogletree ML, Allen GT. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J Pharmacol Exp Ther. 1992 Feb;260(2):789-94. PubMed PMID: 1531361.

6: Takahara K, Murray R, FitzGerald GA, Fitzgerald DJ. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem. 1990 Apr 25;265(12):6836-44. PubMed PMID: 2139029.